Evidence map›Paper›PMID 39562492›Full record

Trial reportThe European journal of health economics : HEPAC : health economics in prevention and care2025

Cost-utility of cochlear implantation in single-sided deafness and asymmetric hearing loss: results of a randomized controlled trial.

Mathieu Marx, Michaël Mounié, Isabelle Mosnier, Frédéric Venail, Michel Mondain, Alain Uziel, David Bakhos, Emmanuel Lescanne, Yann N'Guyen, Daniele Bernardeschi and 9 more

Abstract readRandomized Controlled TrialMulticenter StudyPragmatic Clinical Trial
In one paragraph

Trial report in The European journal of health economics : HEPAC : health economics in prevention and care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. More than 20 years of cochlear implantation in adults with acquired single-sided deafness or asymmetric hearing loss: long term clinical outcomes of 78 subjects implanted at the Antwerp University Hospital.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Mathieu MarxService d'Otologie, Otoneurologie et ORL Pédiatrique, Hôpital Pierre-Paul Riquet, CHU Toulouse Purpan, Place du Dr Baylac, Toulouse Cedex, 31059, France. marx.m@chu-toulouse.fr.ORCID http://orcid.org/0000-0001-8295-8885
Michaël MouniéUnité d'Evaluation Médico-Economique, CHU Toulouse, Toulouse, France.
Isabelle MosnierUnité Fonctionnelle Implants Auditifs, ORL, GH Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
Frédéric VenailService d'ORL, Hôpital Gui de Chauliac, CHU Montpellier, Montpellier, France.
Michel MondainService d'ORL, Hôpital Gui de Chauliac, CHU Montpellier, Montpellier, France.
Alain UzielService d'ORL, Hôpital Gui de Chauliac, CHU Montpellier, Montpellier, France.
David BakhosService d'ORL, Hôpital Bretonneau, CHU Tours, Tours, France.
Emmanuel LescanneService d'ORL, Hôpital Bretonneau, CHU Tours, Tours, France.
Yann N'GuyenUnité Fonctionnelle Implants Auditifs, ORL, GH Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
Daniele BernardeschiUnité Fonctionnelle Implants Auditifs, ORL, GH Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
Olivier SterkersUnité Fonctionnelle Implants Auditifs, ORL, GH Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
Benoit GodeyService d'ORL, Hôpital Pontchaillou, CHU Rennes, Rennes, France.
Gwenaëlle CreffService d'ORL, Hôpital Pontchaillou, CHU Rennes, Rennes, France.
Sébastien SchmerberService d'ORL, CHU Grenoble, Grenoble, France.
Nicolas-Xavier BonneUniversité Lille, Inserm, CHU Lille, Service d'ORL, U1192 - PRISM, Lille, France.
Christophe VincentService d'ORL, Hôpital Salengro, CHU Lille, Lille, France.
Bernard FraysseService d'Otologie, Otoneurologie et ORL Pédiatrique, Hôpital Pierre-Paul Riquet, CHU Toulouse Purpan, Place du Dr Baylac, Toulouse Cedex, 31059, France.
Olivier DeguineService d'Otologie, Otoneurologie et ORL Pédiatrique, Hôpital Pierre-Paul Riquet, CHU Toulouse Purpan, Place du Dr Baylac, Toulouse Cedex, 31059, France.
Nadège CostaUnité d'Evaluation Médico-Economique, CHU Toulouse, Toulouse, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo determine the Incremental Cost-Utility Ratio (ICUR) of cochlear implantation in the treatment of adult patients with single-sided deafness (SSD) and asymmetric hearing loss (AHL).

methodsThis prospective multicenter pragmatic study including a randomized controlled trial (RCT) enrolled 155 subjects with SSD or AHL. Subjects chose a treatment option between: abstention, Contralateral Routing Of the Signal hearing aids, Bone Conduction Device or Cochlear Implant (CI). Participants who opted for CI were then randomized between two arms: "immediate CI" where the cochlear implantation was performed within one month and "initial observation" where subjects were first observed. The ICUR of CI was determined at 6 months follow-up by comparing the two arms. Utility was measured using EuroQoL- 5 dimensions (EQ-5D), to calculate the gain in Quality-Adjusted Life Years (QALY). Individual costs were extracted from the French National Health Insurance database. A Markovian MultiState (MMS) model assessed the ICUR evolution over the lifetime horizon.

resultsAmong the 155 included participants, 51 opted for a CI and were randomized. For a 6 months follow-up period, the ICUR was €422,279/QALY gained after CI. Using the MMS model, the ICUR of CI decreased to €57,561/QALY at 10 years follow-up, €38,006/QALY at 20 years, and dropped to €26,715 at 50 years. In the participants with severe tinnitus, mean ICUR was €31,105/QALY at 10 years.

conclusionsCI can be considered as an efficient treatment in SSD and AHL from 20 years follow-up in the global population, and before 10 years follow-up in patients with severe associated tinnitus.

Indexed as

Cochlear ImplantationDeafnessHearing Loss, UnilateralAdultAgedCochlear ImplantsCost-Benefit AnalysisFemaleFranceHearing AidsHumansMaleMiddle AgedProspective StudiesQuality-Adjusted Life YearsAsymmetric hearing lossCochlear implantICURSingle-sided deafnessTinnitus

Identifiers

PMID39562492
PMCPMC12204948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.